Intravenous Infusion of Human Adipose Mesenchymal Stem Cells Modifies the Host Response to Lipopolysaccharide in Humans: A Randomized, Single-Blind, Parallel Group, Placebo Controlled Trial

DESIREE PERLEE,a,aa LONNEKE A. VAN VUGHT,a BRENDON P. SCICLUANA,a,b ANJA MAAG,a RENÉ LUTTER,c ELLES M. KEMPER,d CORNELIS VAN ’T VEER,a MARIE A. PUNCHARD,e JESÚS GONZÁLEZ,e MARIE PAULE RICHARD,e WILFRIED DALEMANS,f ELEUTERIO LOMBARDO,e ALEX F. DE VOS,a TOM VAN DER POLL,a,g Key Words. Adipose stem cells • Cellular therapy • Clinical trials • Mesenchymal stem cells

ABSTRACT

In experimental models, mesenchymal stem cells (MSCs) can modulate various immune responses implicated in the pathogenesis of sepsis. Intravenous injection of lipopolysaccharide (LPS) into healthy subjects represents a model with relevance for the host response to sepsis. To explore the use of MSCs in sepsis, we determined their effect on the response to intravenous LPS in a randomized study in 32 healthy subjects with four treatment arms: placebo or allogeneic adiposeMSCs (ASCs) intravenously at either 0.25 $\times$ 10^6, 1 $\times$ 10^6, or 4 $\times$ 10^6 cells/kg; all subjects received LPS intravenously (2 ng/kg) one hour after the end of ASC infusion (Trial Register number 2014-002537-63, clinicaltrials.gov identifier NCT02328612). Infusion of ASCs was well tolerated. The high ASC dose increased the febrile response, exerted mixed pro-inflammatory (enhanced interleukin-8 and nucleosome release) and anti-inflammatory effects (increased interleukin-10 and transforming growth factor-β release), and enhanced coagulation activation and reduced the fibrinolytic response. Blood leukocyte transcriptome analyses showed a biphasic effect of ASCs on the LPS response: at 2 hours post LPS, ASC-infused subjects displayed higher expression of genes involved in innate immune pathways, whereas at 4 hours post LPS these subjects had lower expression of innate immune pathway genes. Infusion of ASCs did not modify the “ex vivo” responsiveness of whole blood to various bacterial agonists. These results indicate that intravenous infusion of allogeneic ASCs (4 $\times$ 10^6 cells/kg) has a variety of pro-inflammatory, anti-inflammatory, and procoagulant effects during human endotoxemia. Further studies are needed to assess the safety and efficacy of ASCs in sepsis patients. Stem Cells 2018;36:1778–1788

SIGNIFICANCE STATEMENT

Mesenchymal stem cells have multiple immune modulatory properties that could benefit the treatment of sepsis. Infusion of mesenchymal stem cells improved outcome in preclinical sepsis models and is currently investigated in clinical trials in patients with sepsis or adult respiratory distress syndrome. This study used the human endotoxemia model to evaluate the biological activity of intravenously infused adipose mesenchymal stem cells in a controlled setting with relevance for sepsis pathophysiology. Infusion of adipose stem cells was well tolerated and at the highest dose tested associated with time-dependent proinflammatory and anti-inflammatory effects, as well as mild procoagulant features. These results may improve insight into the mechanism of action of mesenchymal stem cell therapy in sepsis.

INTRODUCTION

Sepsis is a clinical syndrome characterized by a dysregulated host response to an infection resulting in organ failure [1, 2]. Sepsis remains a major cause of morbidity and mortality worldwide despite the use of antibiotics and well-equipped intensive care facilities. In the last decade, hospital-treated sepsis had an estimated worldwide population incidence rate of
437 cases per 100,000 person years [3]. The current case fatality rate of sepsis is around 25% [3].

In sepsis, the balance between the pro-inflammatory and anti-inflammatory immune response is disturbed with a failure to return to homeostasis, resulting in sustained hyperinflammation with collateral tissue damage, combined with immune suppression [1, 2]. In spite of our increased knowledge of the pathogenesis of sepsis, immune modulatory therapies have thus far been unsuccessful in improving the outcome of this syndrome [1, 2, 4]. As such, there is a need for newer therapeutic approaches. Adult mesenchymal stem cells (MSCs) could potentially have clinical relevance in this context [5–9].

In recent years, MSCs have emerged as potent therapeutic tools based on their capacity to modulate immune responses and their low immunogenicity [5]. MSCs can exert many different immunomodulatory effects that theoretically could be beneficial in sepsis, including inhibition of microbial growth, reduction of pro-inflammatory cytokine release with concurrent enhancement of anti-inflammatory cytokine production, attenuation of inflammatory cell adhesion to endothelium, stimulation of endothelial regeneration, and inhibition of apoptosis [5–8]. In accordance, treatment with MSCs improved a variety of outcome parameters in animal models of sepsis [10–20].

Intravenous injection of purified lipopolysaccharide (LPS)—a component of the outer membrane of Gram-negative bacteria—into healthy subjects is a well-characterized model of human inflammation [21, 22]. While the model of human endotoxemia does not capture the full pathophysiology of clinical sepsis, it represents a controlled experimental setting in which the induction and regulation of systemic host responses with relevance for sepsis pathogenesis can be studied [21, 22]. Here, we sought to evaluate the effect of intravenous infusion of allogeneic adipose MSCs (ASCs) on the early inflammatory response to intravenous LPS.

METHODS

Subjects and Study Design

This was a phase I, randomized, single-blind, parallel group, placebo-controlled study in 32 healthy male subjects (study acronym CELLULa; Trial Register number 2014-002537-63, clinicaltrials.gov identifier NCT02328612). The Dutch Central Committee on Research Involving Human Subjects (CCMO) and the Medical Ethics Committee of the Academic Medical Center (AMC), Amsterdam (the Netherlands) approved the study. Written informed consent was obtained from all subjects. Medical history, physical examination, hematological and biochemical screening, and electrocardiograms of all participants were normal. Block randomization was performed by the AMC pharmacist using nQuery; study subjects were blinded for treatment allocation.

ASCs were prepared at TiGenix SAU (Madrid, Spain) as described previously [23]. In short, allogeneic ASCs were obtained from adipose tissue from a healthy donor and expanded until population doublings 12–16, when cells were cryopreserved. Prior to administration, cells were thawed, recovered from cryopreservation by in vitro culture, formulated in Ringer’s lactate (at a concentration of 2.5 million ASCs/ml) and infused intravenously (4 ml/minute) at 0.25 × 10^6, 1 × 10^6, or 4 × 10^6 cells/kg (n = 8 patients per dose). ASCs fulfilled the ISCT criteria for MSCs and were thoroughly checked for viability, population doublings, morphology, potency, identity, purity, sterility and genetic stability, among other quality controls. One hour after the end of intravenous ASC or placebo infusion, subjects were infused with LPS over one minute (2 ng/kg; from Escherichia coli, U.S. standard reference endotoxin, kindly provided by Anthony Saffredini, National Institute of Health, Bethesda, MD). This dose has been used extensively by us and others to induce reproducible inflammatory responses in healthy humans (for reviews, see [21, 22, 24, 25] and references herein).

Oral temperature, blood pressure, oxygen saturation (by pulse oximetry), respiratory rate, and heart rate were measured at half-hour intervals. Clinical symptoms characteristic of endotoxemia such as headache, chills, nausea, vomiting, photophobia and myalgia were recorded every 30 minutes using a graded scale (0, absent; 1, mild; 2, moderate; 3, severe).

EDTA-anticoagulated, citrate-anticoagulated, and heparin-anticoagulated venous blood was collected before treatment administration (baseline), directly before LPS injection (t = 0 hours) and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, and 24 hours thereafter. In addition, blood was collected in PAXgene tubes (Becton-Dickinson, Vianen, the Netherlands) at baseline 0, 2, 4, 6, and 24 hours for mRNA analysis. EDTA-anticoagulated and citrate-anticoagulated plasma was collected by centrifugation at 1,750 g for 10 minutes at 4 °C and stored at ~80°C until analysis.

Assays

All measurements, except thrombin-antithrombin complexes (TATc; citrated plasma), were performed in EDTA-anticoagulated plasma. C-reactive protein (CRP) was measured by immunoturbidimetric assay (Roche Diagnostics, Almere, the Netherlands). Tumor necrosis factor (TNF), interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-13, IL-12p40, interferon (IFN) y, D-dimer, tissue-type plasminogen activator (tPA), plasminogen activator inhibitor type 1 (PAI-1), soluble intercellular adhesion molecule 1 (ICAM-1), soluble E-selectin, soluble vascular adhesion molecule 1 (VCAM-1), and myeloperoxidase (MPO) were measured with Luminex multiplex assay (Affymetrix eBioscience, Santa Clara, CA). Transforming growth factor beta (TGFβ) was measured by ELISA (eBioscience), as were LL-37 (Hycult Biotech, Uden, the Netherlands), elastase-α1-antitrypsin complexes and nucleosomes (both Sanquin, Amsterdam, the Netherlands) [26, 27], and TATc (Affinity Biologicals, Ancaster, Ontario, Canada). IL-2, IL-4, IL-5, IL-13, and IFNγ were only measured in supernatants of whole blood ex vivo stimulations.

Fibrin Generation Assay

Fibrin generation was assessed spectrophotometrically by the fibrin polymerization method as described previously [28]. In short, citrated platelet poor plasma was diluted in 25 mM Heps, 137 mM NaCl, 0.1% ovalbumine with or without 25,000 ASCs (from two different donors) in phosphate buffered saline, and with or without monoclonal antihuman tissue factor antibody (Sekisui, Stamford, CT; 10 μg/ml) in round bottom 96 well plates with Immunolon 2-high-binding coating (Fisher Scientific, Landsmeer, the Netherlands). Plasma was incubated at 37°C for 5 minutes and fibrin generation was initiated by prewarmed 25 mM Heps, 137 mM NaCl, 0.1% ovalbumin, and 17 mM CaCl2. Absorption at 405 nm was measured for 60 minutes with 15 seconds intervals in the
SpectraMax microplate reader (Molecular Devices, Sunnyvale, CA). Results are expressed as percentage tissue factor clot activity.

RNA Preparation and Microarrays
RNA was isolated from PAXgene tubes using the PAXgene Blood miRNA isolation kit (PreAnalytiX, Qiagen, Venlo, the Netherlands) as described by the manufacturer. Total RNA yield and purity (260 nm:280 nm) were determined spectrophotometrically (Nanodrop). RNA integrity was assessed by bioanalysis (Agilent). RNA with integrity number (RIN) > 6 was included for microarrays, which applied to all samples obtained. RNA was hybridized to the Affymetrix Human Genome U219 96-array chip and scanned by means of the GeneTitan instrument (Affymetrix) at the Cologne Center for Genomics, Cologne, Germany. Preprocessing and quality control of the scans were performed by using the affy method (version 1.36.1) [29] in the R statistical computing environment (version 3.3.2). Array data were background corrected by Robust Multi-array Average (RMA), quantiles-normalized, and summarized by median-polish. The resultant 49,386 probe intensities were log-transformed and filtered by means of a 0.5 variance cutoff using the genefilter method [30]. In this way, 24,646 expressed probes in at least one sample were recovered. The occurrence of nonexperimental chip effects was evaluated by means of the surrogate variable analysis method (version 3.4.0) [31] and corrected by the empirical Bayes method combat [32]. Comparison between groups was performed by moderated t statistics implemented in the empirical Bayesian linear models method limma (version 3.14.4) [33–36]. Throughout Benjamini–Hochberg multiple comparison adjusted probabilities [37] (adjusted p < .05) defined significance. Pathway analysis was performed by means of Ingenuity pathway analysis (IPA, www.ingenuity.com) specifying the Ingenuity knowledgebase as reference and human species. All other parameters were default. Significance was evaluated by Fisher’s exact test Benjamini–Hochberg adjusted p values (adjusted p < .05). Normalized and non-normalized array data are accessible through the Gene Expression Omnibus with accession GSE108685.

Whole Blood Stimulations
Heparin-anticoagulated whole blood was obtained at baseline 0, 4, and 24 hours, and incubated ex vivo for 4 or 24 hours without stimulus (control) or stimulated with LPS (200 ng/ml; from E. coli 0111:B4, ultrapure; Bio-Connect, Huissen, the Netherlands), Lipoteichoic acid (LTA 10 μg/ml; from Staphylococcus aureus, purified; Bio-Connect, Huissen, the Netherlands), heat-killed S. aureus or E. coli (both equivalent to 0.5 × 10^8 CFU/ml), or anti-CD3/CD8 (respectively 1 μg/ml and 5 μg/ml, both Sanquin, Amsterdam, the Netherlands). Cytokines were measured in supernatants as readouts for monocyte activation (TNF-α, IL-1β, IL-10) or lymphocyte activation (IL-2, IL-4, IL-5, IL-13, IFN-γ) using assays described above.

Statistical Analysis
Between-group comparisons of all variables, except cytokine data of whole blood stimulations, were done by two-way repeated measures ANOVA, if significant followed by Bonferroni post hoc analysis. Cytokine data of whole blood stimulations was analyzed by Kruskal–Wallis test followed by a Mann–Whitney U test where appropriate. Data are expressed as mean and SD. Analyses were performed using GraphPad Prism version 5.00 for Windows (GraphPad Software, San Diego, CA). A two-sided p-value < .05 was considered significant.

RESULTS
Vital Signs, Clinical Symptoms, and Acute Phase Response
In all, 32 male subjects were enrolled and completed the study between November 2014 and March 2015 (Fig. 1). Demographics
ASC Infusion Does Not Influence LPS-Induced Leukocyte Responses

As expected [22], infusion of LPS induced a transient monocytopenia and lymphocytopenia; these responses were not influenced by ASC infusion (Supporting Information Fig. S2). LPS injection also elicited a neutrophilic leukocytosis (Fig. 2A), accompanied by neutrophil degranulation as indicated by transient rises in the plasma concentrations of elastase-α1-antitrypsin complexes (Fig. 2B) and MPO (Fig. 2C), which were not significantly modified by ASC infusion. The plasma levels of LL-37, a peptide present in lysosomes of neutrophils (and macrophages) and implicated in the antimicrobial properties of ASCs [38], were not altered in any of the treatment groups (data not shown). These results suggest that ASC infusion has no major effects on neutrophil responses during human endotoxemia.

ASC Infusion Has Both Proinflammatory and Anti-Inflammatory Effects on LPS-Induced Activation of the Cytokine Network

To obtain insight into the effect of ASCs on the LPS-induced activation of the cytokine network, we measured a set of proinflammatory cytokines (TNF, IL-1β, IL-6, IL-8, and IL-12p40) and anti-inflammatory cytokines (IL-10 and TGF-β) (Fig. 3). Intravenous LPS elicited transient rises in the plasma concentrations of TNF, IL-6, IL-8, IL-12p40, and IL-10 (Fig. 3). ASC infusion did not modify LPS-induced TNF, IL-6, or IL-12p40 release, albeit in the high dose group there was a tendency toward reduced IL-12p40 release. Administration of all three ASC doses was associated with increased LPS-induced IL-8 release (p < .01, <.05, and <.05 vs. placebo, respectively). Infusion of ASCs at 4 × 10^6 cells/kg was associated with higher plasma IL-10 and TGF-β levels after LPS injection (Fig. 3, p < .01 vs. placebo). IL-1β remained undetectable in virtually all samples and was not different between groups (data not shown). Together, these results suggest that ASC infusion has mixed proinflammatory (enhanced IL-8 release) and anti-inflammatory effects (trend to reduce IL-12p40 and increased IL-10 and TGF-β release) on the cytokine network during human endotoxemia.

Infusion of ASCs Exerts Procoagulant Effects Without Influencing LPS-Induced Endothelial Cell Activation

Activation of coagulation, fibrinolysis and endothelial cells are hallmark features of sepsis [39, 40], and the human endotoxemia model is suitable to study the mechanisms influencing these responses [41]. LPS injection elicited transient increases in the plasma levels of TATc (Fig. 4A) and D-dimer (Fig. 4B), reflecting activation of the coagulation system. Infusion of ASCs at 4 × 10^6 cells/kg was associated with increased plasma TATc and D-dimer concentrations relative to the control group (p < .01 and <.001, respectively); these increases occurred early, that is, already before LPS injection for TATc and directly after LPS administration (before a rise was detected in the control group) for D-dimer. ASCs at 1 × 10^6 cells/kg also enhanced LPS-induced D-dimer release (p < .05 vs. placebo). LPS provoked transient increases in the plasma concentrations of TPA (indicating activation of fibrinolysis; Fig. 4C) and PAI-1 (a main inhibitor of fibrinolysis; Fig. 4D). High dose ASCs (4 × 10^6 cells/kg) inhibited the LPS-induced increase in plasma...
tPA levels ($p < .01$ vs. placebo). ASC infusion did not modify PAI-1 concentrations. Endothelial cell activation after LPS injection was reflected by rises in the plasma concentrations of soluble E-selectin (Fig. 4E) and soluble VCAM-1 (Fig. 4F); this response was not altered by ASC infusion. Likewise, the LPS-induced increase in plasma soluble ICAM-1 concentrations, which can be derived from endothelial cells or leukocytes, was not affected by ASC infusion (Fig. 4G). Previous investigations have documented procoagulant activity associated with MSCs from different sources [42–47], which has been linked to expression of tissue factor [42–47], a protein capable of activating the coagulation cascade via Factor VII [48]. In accordance, ASCs used in our in vivo study enhanced fibrin generation in vitro, which could be completely inhibited by an anti-tissue factor antibody (Fig. 4H). Together, these results indicate that ASC infusion at a high dose is associated with a transient procoagulant effect, detectable already before LPS injection and possibly tissue factor dependent, and a blunted fibrinolytic response.

**ASC Infusion Increases Plasma Nucleosome Levels**

Sepsis is associated with elevated plasma levels of nucleosomes, which is considered to reflect enhanced cell death [49,50]. Considering that ASCs exert antiapoptotic effects [5,6,8,10], we were interested to determine the impact of ASC infusion on nucleosome release during endotoxemia. Intravenous LPS elicited a transient rise in plasma nucleosome levels peaking after 3 hours (Fig. 5). Infusion of ASCs at $4 \times 10^6$ cells/kg was accompanied by an early increase in plasma nucleosome levels peaking after 1.5 hours that was significantly higher than in control subjects ($p < .01$).

**ASC Infusion Modifies the Blood Leukocyte Transcriptome in a Time-Dependent Biphasic Manner**

In order to better understand the capacity of ASCs to influence the host response during endotoxemia, we performed a genome-wide scan of gene expression in blood leukocytes. At 2, 4, and 6 hours after LPS administration, the leukocyte transcriptome in the placebo group was characterized by a dramatic alteration in gene expression with $>8,000$ significantly different genes relative to baseline (Supporting Information Fig. S3A). At 24 hours, only three genes were significantly different in expression. Ingenuity pathway analysis revealed significant overrepresentation of various canonical signaling pathways (Supporting Information Fig. S3B). Overexpressed genes were associated to prototypical innate immune pathways, including nuclear factor (NF)-kB signaling, Toll-like receptor (TLR) signaling, triggering receptor expressed on myeloid cells (TREM)-1 signaling, and IL-6 signaling; underexpressed genes were predominantly associated to metabolic and adaptive immune pathways. Comparing the LPS-induced leukocyte transcriptome, ASC groups at low and medium dose revealed no statistically significant differences to the placebo group (Supporting Information Fig. S4). However, we uncovered statistically significant alterations in subjects treated with high dose ($4 \times 10^6$ cells/kg). Two hours after LPS administration,
Figure 4. ASC infusion has a procoagulant effect without influencing lipopolysaccharide (LPS)-induced activation of endothelial cells. Mean (with SD) plasma concentrations of TATc (A), D-dimer (B), IPA (C), PAI-1 (D), soluble E-selectin (E), soluble VCAM-1 (F), and soluble ICAM-1 (G) after intravenous LPS administration (2 ng/kg, t = 0) 1 hour after the completion of intravenous infusion of Ringer’s lactate (placebo) or ASCs (0.25 × 10^6, 1 × 10^6, or 4 × 10^6 cells/kg). TATc levels were significantly changed at T0 (**), T0.5 (**), T1-1.5 (**), and T2 (**) after treatment with 4 × 10^6 cells/kg; D-dimer levels were significantly changed at T2 (**), T3 (**), and T4 (**) after treatment with 1 × 10^6 cells/kg and at T1.5-6 (**) and T8 (*) after treatment with 4 × 10^6 cells/kg. IPA levels were significantly changed at T0 (**) and T6 (*) after treatment with 4 × 10^6 cells/kg. *p < .05, **p < .01, ***p < .001 versus the control group (two-way repeated measures ANOVA). (H): in vitro fibrin generation in normal pool plasma by ASCs. Tissue factor (TF) dependence is shown by a blocking TF antibody in ASCs of two different donors. Mean (with SD) tissue factor clot activity (%) of ASCs derived from two different donors (N = 4). *p < .05. Abbreviations: ASC, adipose mesenchymal stem cells; ICAM-1, intercellular adhesion molecule-1; PAI-1, plasminogen-activator inhibitor type I; TATc, thrombin-antithrombin complexes; tPA, tissue-type plasminogen activator; VCAM-1, vascular cell adhesion molecule-1.

138 genes were significantly overexpressed and 236 genes were underexpressed in high-dose ASC-treated subjects relative to the control group. Supporting Information Table S4 depicts the topmost significant genes (adjusted p < .05) considering fold changes >2 or <−2. At 4 hours, we found 56 overexpressed genes and 92 underexpressed genes, and at 6 hours we detected 4 overexpressed and 7 underexpressed genes in high-dose ASC-treated subjects relative to controls; no differences were observed at 24 hours. Pathway analysis of the altered genes at 2 hours revealed significant overrepresentation of overexpressed genes linking with predominantly innate immune mechanisms including NF-κB signaling, TLR signaling, and p38 mitogen activated protein kinase (MAPK) signaling (Fig. 6A). No significant associations were uncovered for underexpressed genes. At 4 hours, analysis of overexpressed genes in the high-dose ASC group revealed overrepresentation for various metabolic, protein degradation, and cell growth pathways. Interestingly, underexpressed genes in the high-dose ASC group at 4 hours significantly overrepresented a number of innate immune pathways that included NF-κB signaling, TNF receptor signaling, and production of nitric oxide and reactive oxygen species in macrophages. Supporting Information Figure S5 illustrates the biphasic effect of high-dose ASC infusion on LPS-induced NF-κB signaling in blood leukocytes. Overall, these findings suggest that high-dose ASC treatment may influence the blood leukocyte host response in a time-dependent biphasic manner with innate immune mechanisms enhanced early after LPS administration (2 hours) and blunted shortly thereafter (4 hours).

**DISCUSSION**

Ample preclinical evidence indicates that MSCs can be an effective adjunctive therapy in patients with sepsis or noninfectious critical illness [5–9]. A recent meta-analysis including 20 controlled experiments in preclinical sepsis models reported that treatment with MSCs reduced the odds of mortality of

ASC Infusion Does Not Modify Leukocyte Responsiveness upon “Ex Vivo” Stimulation

Sepsis is associated with a reduced responsiveness of monocytes and lymphocytes upon stimulation [2, 51]. This immune suppressive feature can be reproduced by intravenous injection of LPS, that is, blood leukocytes obtained several hours after LPS administration are less capable of releasing cytokines upon restimulation ex vivo [52, 53]. Considering the broad immune modulatory actions of ASCs, we wished to establish whether ASC infusion is able to modify cellular hyporesponsiveness during endotoxemia. For this, we stimulated the whole blood obtained at baseline, directly before LPS injection and at 4 and 24 hours thereafter, ex vivo with bacterial agonists (LPS, LTA, *S. aureus*, or *E. coli*) or with a T cell stimulus (anti-CD3/CD28) for 4 or 24 hours. Blood leukocytes harvested 4 hours after LPS injection showed a reduced capacity to release cytokines upon stimulation, which was not influenced by ASC infusion at any dose. Data are shown for TNF and IL-10 after 24-hour LPS stimulation (Fig. 7A) and for IFN-γ and IL-13 after 24-hour stimulation with anti-CD3/CD28 (Fig. 7B).
Experimental sepsis by approximately 73% over a range of investigational conditions [54]. To further explore the safety and potential use of intravenous infusion of ASCs in the treatment of sepsis patients, we used the well-described model of human systemic inflammation induced by intravenous injection of LPS [21, 22] to obtain insight into the effect of ASCs on the induction of host immune responses with relevance for sepsis pathogenesis. We show that intravenous infusion of ASCs is well tolerated, at any dose tested. At a high dose (4 × 10^6 cells/kg), ASCs had clear signs of biological activity, exerting a variety of proinflammatory, anti-inflammatory, and procoagulant effects during human endotoxemia. Notably, while many previous studies examined the effect of MSCs in inflammation and sepsis models in animals [5–9, 54], this investigation is the first to study the effect of MSCs on inflammatory responses in humans.

Excessive neutrophil activation may cause tissue injury in sepsis [55]. MSCs have been reported to inhibit neutrophil oxidative burst and degranulation in vitro, as measured by extracellular release of MPO and elastase [56, 57], and to strongly attenuate neutrophil-mediated damage in a model of immune complex-mediated vasculitis in vivo [56]. However, we did not detect a significant effect of ASCs on the induction of neutrophil leukocytosis or neutrophil degranulation during human endotoxemia. Notably, protective role during polymicrobial sepsis in mice [10]. Here, we showed that infusion of high-dose ASCs enhanced not only the release of IL-10 upon LPS injection, but also elicited the release of TGF-β, which was not induced in subjects receiving placebo or lower doses of ASCs. TGF-β has pleiotropic functions and is involved in both suppressive and inflammatory immune responses [64]. TGF-β can render macrophages and monocytes hyporesponsive to LPS [65] and therefore may play an anti-inflammatory role during endotoxemia and sepsis [66]. Hence, elevated IL-10 and TGF-β levels in subjects infused with high-dose ASCs point to an anti-inflammatory effect. This is further supported by a tendency to also reduce IL-12p40 release and by the alteration of the blood leukocyte gene expression at 4 hours after LPS showing reduced activation of NF-kB signaling, TNF receptor signaling, and production of nitric oxide and reactive oxygen species. On the other hand, infusion of high-dose ASCs was also associated with proinflammatory effects, most notably enhanced IL-8 release, and increased TLR, MAPK, and NF-kB signaling in blood leukocyte gene expression at 2 hours after LPS injection. In accordance, short-term exposure of MSCs to LPS in vitro can induce a proinflammatory response [67, 68] and a comprehensive

![Figure 5](image_url)  
**Figure 5.** Infusion of adipose mesenchymal stem cells (ASCs) enhance lipopolysaccharide (LPS)-induced nucleosome release. Mean (with SD) plasma concentrations of nucleosomes after intravenous LPS administration (2 ng/kg, t = 0) 1 hour after the completion of intravenous infusion of Ringer’s lactate (placebo) or ASCs (0.25 × 10^6, 1 × 10^6, or 4 × 10^6 cells/kg), Nucleosome levels were significantly changed at T0.5 (***) and T1-2 (****) after treatment with 4 × 10^6 cells/kg. ***, p < .01; ****, p < .001 versus the control group (two-way repeated measures ANOVA).

![Figure 6](image_url)  
**Figure 6.** Time dependent effects of adipose mesenchymal stem cells (ASCs) infusion on the lipopolysaccharide (LPS)-induced leukocyte transcriptome. (A): Ingenuity pathway analysis of the high ASC dose group at 2 hours after LPS administration revealed statistically significant enrichment for only overexpressed genes (red). Typical pro-inflammatory pathways, notably NF-kB signaling, were potentiated by the high cell dose. (B): Ingenuity pathway analysis of the high ASC dose at 4 hours after LPS administration revealed statistically significant enrichment for both overexpressed (red) and underexpressed (turquoise) genes. Most particular, NF-kB signaling was underexpressed in high cell dose samples compared to placebo after LPS administration. No differences were uncovered at baseline. Only 1 gene (NFKBIA) was differentially expressed at 0 hours in high cell dose compared to placebo. Array data are accessible through the Gene Expression Omnibus with accession GSE108685 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE108685).
analysis of gene expression in LPS-stimulated MSCs revealed induction of multiple proinflammatory genes with NF-κB as the central node [69]. Together, these results suggest that ASC infusion has mixed proinflammatory and anti-inflammatory effects during human endotoxemia, which may vary in a time-dependent manner.

In our study, infusion of high ASC dose was associated with a transient procoagulant effect as reflected by elevated plasma levels of TATc and D-dimer, which already became apparent before or shortly after LPS injection, that was not related to any clinical adverse event. In additional in vitro studies, we showed that the ASCs used here, like MSCs from other sources [42–47], express tissue factor-dependent procoagulant activity. Tissue factor is the main driver of coagulation activation after intravenous LPS injection in humans [70, 71], and we consider it likely that MSC-associated tissue factor is responsible for the enhanced coagulation activation in this model. Akin to our results, patients infused with bone-marrow derived MSCs for treatment of complications of hematopoietic stem cell transplantation showed a rise in plasma TATc without clinically evident thromboembolic events [42]. Likewise, infusion of placenta-derived decidual stromal cells resulted in a transient rise in plasma D-dimer levels in the absence of any thrombotic event in these patients [46]. High-dose ASC infusion inhibited the release of tPA, which is expected to reduce fibrinolysis, which may further contribute to a procoagulant effect. Procoagulant effects of MSCs in vivo have also been documented in experimental animals; for example, infusion of high doses of MSCs into mice was associated with the formation of fibrin clots in lungs [44] and in a porcine model of acute myocardial infarction, intracoronary delivery of bone-marrow-derived MSCs was associated with in situ microvascular thrombosis [45]. Although caution is warranted and close monitoring of patients is needed, the clinical relevance of the procoagulant effects of MSCs in humans is not certain considering that MSCs of a variety of sources have been proven safe in patients and thromboembolic events have not been reported [72, 73].

Comprehensive analyses of the blood leukocyte transcriptome suggested a biphasic effect of ASCs on LPS-induced gene expression. Most strikingly, ASC infusion was associated with early enhancement (2 hours post-LPS) and later suppression (4 hours post-LPS) of NF-κB signaling in blood leukocytes. Importantly, the inflammatory microenvironment is required for MSCs to activate gene expression pathways and exert their immunoregulatory capability [74, 75], which therefore may require some hours from the time of infusion. Thus, proinflammatory cytokines like IFN-γ, TNF, and IL-β can activate MSCs to exert immunosuppressive functions [76, 77]. Our data suggest that the initial inflammatory response elicited by intravenous LPS may have contributed to activate the ASCs, resulting in the immune suppressive effects of ASCs detected beyond 2 hours post LPS. This also points to a limitation of the human endotoxemia model, which might not be the best option to investigate MSC immunomodulatory properties, due to differential kinetics between the transient and short LPS effects and the time needed by MSC for activation and activity. This model is associated with activation of innate immune pathways that—although resembling responses seen in patients with sepsis in a qualitative way—occurs in a very rapid, short-lived, and transient way, unlike sepsis-associated alterations, which are more severe and sustained. Because of this limitation, subjects received ASCs prior to LPS, whereas posttreatment would better resemble the clinical scenario.
Release of nucleosomes is considered to reflect cell death [78, 79]. Elevated circulating levels of nucleosomes have been detected in several conditions, including trauma, ischemia–reperfusion injury, and sepsis [49, 50, 78, 79]. Here, we report the transient release of nucleosomes after intravenous injection of LPS into healthy subjects. Preliminary investigations done in our laboratory suggest that the main cellular source of circulating nucleosomes in this model is neutrophils. Infusion of ASCs was associated with an earlier and stronger rise in plasma nucleosome levels upon intravenous LPS injection, suggestive of enhanced neutrophil turnover. Possibly, the increased early proinflammatory response as detected by the blood transcriptome played a role herein. Although these data contrast with the effect of MSCs in animal models of sepsis and endotoxemia, where MSCs diminished apoptosis of cells in various organs [11, 14, 80], they are not necessarily contradic-
tive. Indeed, intravenous injection of low-dose LPS into healthy subjects induces only a mild and transient response, whereas experimental sepsis in animals or clinical sepsis on the intensive care unit are associated with sustained hyperinflammation with injury to multiple cell types in multiple organs [2, 51, 78].

Additionally, it cannot be ruled out that the rise in plasma nucleosomes might originate from the clearance and elimination of the infused ASCs, as it is known that MSCs are short lived after administration [81, 82].

Sepsis is associated with immune suppression characterized by (among other) a reduced capacity of blood monocytes and lymphocytes to release proinflammatory cytokines upon stimulation ex vivo [2, 51]. The model of human endotoxemia reproduces this state of “reprogramming” in blood leukocytes and has been used to study the mechanisms involved and to evaluate potential strategies to prevent this [52, 53, 83, 84]. MSCs exert broad immune modulatory effects on many different cell types including monocytes and lymphocytes, characterized by inhibition of (proinflammatory) type 1 cytokines and enhancement of (anti-inflammatory) type 2 cytokines [58–60, 85]. As such, in theory MSCs could potentiate this feature of immune suppression after in vivo exposure to LPS. However, using a panel of monocyte and lymphocyte stimulants, we were not able to detect such an effect in this rapid and transient model. It remains to be established whether MSCs influence cellular reprogramming at tissue levels and/or during conditions of more sustained immune suppression.

MSCs are now tested as a potential adjunctive therapy in inflammatory diseases including sepsis and acute respiratory distress syndrome (clinicaltrials.gov identifiers NCT02883803) [86, 87]. While the immune modulatory effects of MSCs have been studied in a variety of animal models of inflammation and infection [5–9, 54], the current investigation is the first to report on the effects of MSCs in humans, using a well-established model of systemic inflammation induced by intravenous injection of LPS. Our results indicate that in this transient condition of mild inflammation intravenous infusion of allogeneic ASCs was safe and exerted a variety of time-dependent proinflammatory and anti-inflammatory effects, as well as procoagulant features. Despite the limitations of this model, some of our findings confirm earlier immunomodulatory effects in animal models of sepsis. Further testing of ASCs in sepsis patients is warranted to assess their safety and efficacy, to determine their effects on the host response during sepsis, and to enhance insight in their mechanism of action.

ACKNOWLEDGMENTS

This study was funded by TiGenix.

AUTHOR CONTRIBUTIONS

D.P.: conception and design, collection and/or assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript; L.A.v.V.: conception and design, collection and/or assembly of data, data analysis and interpretation, final approval of manuscript; B.P.S.: collection and/or assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript; A.M. and R.L.: collection and/or assembly of data, data analysis and interpretation, final approval of manuscript; E.M.K., C.v.V., M.A.P., J.G., M.P.R., W.D., and E.L. are full time employees of TiGenix. T.V.D.P. received research funding for mouse studies with stem cells used in the study described in this article. The other authors indicated no disclosure to declare.

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

M.A.P., J.G., M.P.R., W.D., and E.L. are full time employees of TiGenix. T.V.D.P. received research funding for mouse studies with stem cells used in the study described in this article. The other authors indicated no disclosure to declare.

REFERENCES

1 Delano MJ, Ward PA. The immune system’s role in sepsis progression, resolution, and long-term outcome. Immunol Rev 2016;274:330–353.
2 van der Poll T, van de Veerdonk FL, Scicluna BP et al. The immunopathology of sepsis and potential therapeutic targets. Nat Rev Immunol 2017;17:407–420.
3 Fleischmann C, Scherag A, Adhikari NK et al. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med 2016;193:259–272.
4 Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med 2013;369:2063.
5 Ho MS, Mei SH, Stewart DJ. The immuno-
momodulatory and therapeutic effects of mesenchymal stromal cells for acute lung injury and sepsis. J Cell Physiol 2015;230:2606–2617.
6 Lombardo E, van der Poll T, DelaRosa O et al. Mesenchymal stem cells as a therapeutic tool to treat sepsis. World J Stem Cells 2015;7:368–379.
7 Matthay MA, Pati S, Lee JW. Concise review: Mesenchymal stem (stromal) cells: Biology and preclinical evidence for therapeutic potential for organ dysfunction following trauma or sepsis. Stem Cells 2017;35:316–324.
8 Kingsley SM, Bhat BV. Could stem cells be the future therapy for sepsis? Blood Rev 2016;30:439–452.
9 Johnson CL, Soeder Y, Dahike MH. Concise review: Mesenchymal stromal cell-based approaches for the treatment of acute respira-
ory distress and sepsis syndromes. Stem
Cells Translational Medicine 2017;6:1141–1151.
10 Nemeth K, Leelahavanichkul A, Yuen PS et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009;15:42–49.
11 Mei SH, Haitsma JJ, Dos Santos CC et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med 2010;182:1047–1057.
12 Gupta N, Krasnodembskaya A, Kapetanaki M et al. Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia. Thorax 2012;67:533–539.
13 Anderson P, Souza-Moreira L, Morell M et al. Adipose-derived mesenchymal stromal cells induce immunomodulatory macrophages which protect from experimental colitis and sepsis. Gut 2013;62:1131–1141.
14 Sung PH, Chang CL, Tsai TH et al. Adipose-derived mesenchymal stem cell therapy protects against lung and kidney injury in sepsis syndrome caused by cecal ligation puncture in rats. Stem Cell Res Ther 2013;4:155.
15 Hackstein H, Lippitsch A, Krug P et al. Prospectively defined murine mesenchymal stem cells inhibit Klebsiella pneumoniae-induced acute lung injury and improve pneumonia survival. Respir Res 2015;16:123.
16 Amsussen S, Itø H, Traber DL et al. Human mesenchymal stem cells reduce the severity of acute lung injury in a sheep model of bacterial pneumonia. Thorax 2014;69:819–825.
17 Devaney J, Horie S, Masterson C et al. Human mesenchymal stromal cells decrease the severity of acute lung injury induced by E. coli in the rat. Thorax 2015;70:625–635.
18 Mao YX, Xu JF, Seeley EJ et al. Adipose tissue-derived mesenchymal stem cells attenuate pulmonary infection caused by Pseudomonas aeruginosa via inhibiting overproduction of prostaglandin E2. Stem Cells Transl Med 2013;2:231–237.
19 Krasnodembskaya A, Samarani G, Song Y et al. Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol Lung Cell Mol Physiol 2012;302:L1003–L1013.
20 Gonzalez-Rey E, Anderson P, Gonzalez MA et al. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut 2009;58:929–937.
21 Andreassen AS, Krabbe KS, Krogh-Madsen R et al. Human endotoxemia as a model of systemic inflammation. Curr Med Chem 2008;15:1697–1705.
22 Suffredini AF, Noveck RJ. Human endotoxin administration as an experimental model in drug development. Clin Pharmacol Ther 2014;96:418–422.
23 Álvaro-Gracia JM, Jover JA, García-Vicuña R et al. Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (C6x111): Results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial. Ann Rheum Dis 2017;76:196–202.
24 Lowry SF. Human endotoxia: A model for mechanistic insight and therapeutic targeting. Shock 2005;24(suppl 1):94–100.
25 Calvano SE, Coyle SM. Experimental human endotoxia: A model of the systemic inflammatory response syndrome? Surg Infect (Larchmt) 2012;13:293–299.
26 van Montfoort ML, Stephan F, L Morrow MN et al. Circulating nucleosomes and neutrophil activation as risk factors for deep vein thrombosis. Arterioscler Thromb Vasc Biol 2013;33:147–151.
27 Zeerleder S, Zwart B, te Velthuis H et al. A plasma nucleosome releasing factor (NRF) with serine protease activity is instrumental in removal of nucleosomes from secondary necrotic cells. FEBS Lett 2007;581:5382–5388.
28 Bijsterveld NR, Vink R, van Aken BE et al. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol 2004;124:653–658.
29 Gautier L, Cope L, Bolstad BM et al. affy—Analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004;20:307–315.
30 Bourgon R, Gentleman R, Huber W. Independent filtering increases detection power for high-throughput experiments. Proc Natl Acad Sci USA 2010;107:9546–9551.
31 Leek JT, Storey JD. Capturing heterogeneity in gene expression studies by surrogate variable analysis. PLoS Genet 2007;3:1724–1735.
32 Johnson W, Li C, Rabinovic A. Adjusting batch effects in microarray expression data at the probe level. Bioinformatics 2003;19:279–286.
33 Smyth GK. Limma: Linear models for microarray data. In: Gentleman R, Carey VJ, Huber W et al., eds. Bioinformatics and Computational Biology Solutions Using R. New York, NY: Springer, 2005:397–420.
34 van Lieshout MH, Scicula BP, Florquin S et al. NLRP3 and ASC differentially affect the transcriptional response to LPS and cause microvascular obstruction following intracranial delivery: Amelioration by antithrombin therapy. Stem Cells 2015;33:2726–2737.
35 Moll G, Ignatowicz L, Catar R et al. Different procoagulant activity of therapeutically expanded mesenchymal stromal cells derived from bone marrow and placental decidua. Stem Cells Dev 2015;24:2269–2279.
36 Christy BA, Herzog MC, Montgomery RK et al. Procoagulant activity of human mesenchymal stem cells. J Trauma Acute Care Surg 2017;83(suppl 1):S164–S169.
37 Witkowski M, Landmesser U, Rauch U. Tissue factor as a link between inflammation and coagulation. Trends Cardiovasc Med 2016;26:297–303.
38 Zeerleder S, Zwart B, Wulliemen WA et al. Elevated nucleosome levels in systemic inflammation and sepsis. Crit Care Med 2003;31:1947–1951.
39 Zeerleder S, Stephan F, Emonts M et al. Circulating nucleosomes and severity of illness in children suffering from meningococcal sepsis treated with protein C. Crit Care Med 2012;40:3224–3229.
40 Hotchkiss RS, Monneret G, Payen D. Septis-induced immunosuppression: From cellular dysfunctions to immunotherapy. Nat Rev Immunol 2013;13:862–874.
41 van ’t Veer C, van den Pangaart PS, van Zoelen MA et al. Induction of IRAK-M is associated with lipopolysaccharide tolerance in a human endotoxemia model. J Immunol 2007;179:7110–7120.
42 de Vos AF, Pater JM, van den Pangaart PS et al. In vivo lipopolysaccharide exposure of human blood leukocytes induces cross-tolerance to multiple TLK ligands. J Immunol 2009;183:533–542.
43 Lalu MM, Sullivan KJ, Mei SH et al. Evaluating mesenchymal stem cell therapy for sepsis with preclinical meta-analyses prior to initiating a first-in-human trial. Elife 2016;5:e18750.
44 Sonego F, Castanheira FV, Ferreira RG et al. Paradoxical roles of the neutrophil in sepsis: Protective and deleterious. Front Immunol 2016;7:155.
56 Jiang D, Muschhammer J, Qi Y et al. Suppression of neutrophil-mediated tissue damage—A novel skill of mesenchymal stem cells. Stem Cells 2016;34:2393–2406.
57 Mumaw JL, Schmiedt CW, Breidling S et al. Feline mesenchymal stem cells and supernatant inhibit reactive oxygen species production in cultured feline neutrophils. Res Vet Sci 2015;103:60–69.
58 Kim J, Hematti P. Mesenchymal stem cell-educated macrophages: A novel type of alternatively activated macrophages. Exp Hematol 2009;37:1445–1453.
59 Maggini J, Mirkin G, Bognanni I et al. Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS One 2010;5:e9252.
60 Zhang QZ, Su WR, Shi SH et al. Human gingiva-derived mesenchymal stem cells elicit polarization of m2 macrophages and enhance cutaneous wound healing. Stem Cells 2010;28:1856–1868.
61 Wu KH, Wu HP, Chao WR et al. Time-series expression of toll-like receptor 4 signaling in septic mice treated with mesenchymal stem cells. Shock 2016;45:634–640.
62 Pedralla Z, Lunardelli A, Luft C et al. Mesenchymal stem cells decrease splenocytes apoptosis in a sepsis experimental model. Inflamm Res 2014;63:719–728.
63 Gupta N, Su X, Popov B et al. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol 2007;179:1855–1863.
64 Sanjabi S, Oh SA, Li MO. Regulation of the immune response by TGF-beta: From conception to autoimmunity and infection. Cold Spring Harb Perspect Biol 2017;9(6). pii: a022236. doi: 10.1101/cshperspect.a022236.
65 Randow F, Syrbe U, Meisel C et al. Mechanism of endotoxin desensitization: Involvement of interleukin 10 and transforming growth factor beta. J Exp Med 1995;181:1887–1892.
66 Cavaillon JM, Adib-Conquy M. Bench-to-bedside review: Endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit Care 2006;10:233.
67 Romieu-Moreau R, Francois M, Boivin MN et al. Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. J Immunol 2009;182:7963–7973.
68 Waterman RS, Tomchuck SL, Henkle SL et al. A new mesenchymal stem cell (MSC) paradigm: Polarization into a proinflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS One 2010;5:e10088.
69 Kim SH, Das A, Chai JC et al. Transcriptome sequencing wide functional analysis of human mesenchymal stem cells in response to TLR4 ligand. Sci Rep 2016;6:30311.
70 de Jonge E, Dekkers PE, Creasey AA et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000;95:1124–1129.
71 de Pont AC, Moons AH, de Jonge E et al. Recombinant nematode anticoagulant protein c2, an inhibitor of tissue factor/factor VIIa, attenuates coagulation and the interleukin-10 response in human endotoxemia. J Thromb Haemost 2004;2:65–70.
72 Lalu MM, McIntyre L, Pugliese C et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): A systematic review and meta-analysis of clinical trials. PLoS One 2012;7:e47559.
73 Prokopp DJ, Prokop SE, Bertoncello I. Are clinical trials with mesenchymal stem/progenitor cells too far ahead of the science? Lessons from experimental hematology. Stem Cells 2014;32:3055–3061.
74 Bernardo ME, Fibbe WE. Mesenchymal stromal cells: Sensors and switchers of inflammation. Cell Stem Cell 2013;13:392–402.
75 Shi Y, Su J, Roberts Al et al. How mesenchymal stem cells interact with tissue immune responses. Trends Immunol 2012;33:136–143.
76 Singer NG, Caplan Al. Mesenchymal stem cells: Mechanisms of inflammation. Annu Rev Pathol 2011;6:457–478.
77 Ren G, Zhang L, Zhao X et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008;2:141–150.
78 Marsman G, Zeerleder S, Luken BM. Extracellular histones, cell-free DNA, or nucleosomes: Differences in immunostimulation. Cell Death Dis 2016;7:e2518.
79 Silk E, Zhao H, Weng H et al. The role of extracellular histone in organ injury. Cell Death Dis 2017;8:e2812.
80 Shin S, Kim Y, Jeong S et al. The therapeutic effect of human adult stem cells derived from adipose tissue in endotoxic shock model. Int J Med Sci 2013;10:8–18.
81 Eggenhofe E, Luk F, Dahlke MH et al. The life and fate of mesenchymal stem cells. Front Immunol 2014;5:148.
82 Eggenhofe E, Benseler V, Kroemer A et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol 2012;3:297.
83 Leentjens J, Kox M, Koch RM et al. Reversal of immunoparalysis in humans in vivo: A double-blind, placebo-controlled, randomized pilot study. Am J Respir Crit Care Med 2012;186:838–845.
84 Cheng SC, Scicluna BP, Arts RJ et al. Broad defects in the energy metabolism of leukocytes underlie immunoparalysis in sepsis. Nat Immunol 2016;17:406–413.
85 Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105:1815–1822.
86 McIntyre LA, Stewart DJ, Mei SHJ et al. Cellular Immunotherapy for Septic Shock (CISS): A Phase I Clinical Trial. Am J Respir Crit Care Med 2018;197(3):337–347. doi: 10.1164/rccm.201705-1060OC.
87 Wilson JG, Liu KD, Zhuo H et al. Mesenchymal stem (stromal) cells for treatment of ARDS: A phase 1 clinical trial. Lancet Respir Med 2015;3:24–32.